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Summary Introduction Oleandrin, a cardiac glycoside, ex-
erts strong anti-proliferative activity against various human
malignancies in in vitro cells. Here, we report the antitumor
efficacy of PBI-05204, a supercritical C02 extract of Nerium
oleander containing oleandrin, in a human pancreatic cancer
Panc-1 orthotopic model. Results While all the control mice
exhibited tumors by the end of treatment, only 2 of 8 mice
(25 %) treated for 6 weeks with PBI-05204 (40 mg/kg)
showed dissectible tumor at the end of the treatment period.
The average tumor weight (222.9±116.9 mg) in mice treated
with PBI-05204 (20 mg/kg) was significantly reduced from
that in controls (920.0±430.0 mg) (p<0.05). Histopathologic
examination of serial sections from each pancreas with no
dissectible tumor in the PBI-05204 (40 mg/kg) treated group
showed that the pancreatic tissues of 5/6 mice were normal
while the remaining mouse had a tumor the largest diameter of
which was less than 2.3 mm. In contrast, while gemcitabine
alone did not significantly reduce tumor growth, PBI-05204
markedly enhanced the antitumor efficacy of gemcitabine
in this particular model. Ki-67 staining was reduced in
pancreatic tumors from mice treated with PBI-05204
(20 mg/kg) compared to that of control, suggesting that
PBI-05204 inhibited the proliferation of the Panc-1 tumor
cells. PBI-05204 suppressed expression of pAkt, pS6, and
p4EPB1 in a concentration-dependent manner in both Panc-
1 tumor tissues and human pancreatic cancer cell lines,
implying that this novel botanical drug exerts its potent
antitumor activity, at least in part, through down-
regulation of PI3k/Akt and mTOR pathways.
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Introduction
Pancreatic cancer is the fourth most common cause of cancer
deaths in Western society and is one of the leading causes of
cancer deaths worldwide. In 2014, an estimated 46,420 new
cases will be diagnosed, and an estimated 39,590 people in the
United States will die from this disease [1]. Despite progress
made in our understanding of the genetic causes of invasive-
ness of this disease and efforts to improve the treatment of
pancreatic cancer with various therapeutic regimens, the sur-
vival figures for pancreatic cancer have not changed signifi-
cantly over the past four decades [2]. Stage-for-stage, cancer
of the pancreas has the shortest median survival time of all
cancer types. Therefore, there is a critical need to not only
understand the nature and molecular activity of this deadly
disease, but to also develop effective treatments as well.
Finding drugs that can specifically target tumor cells, yet not
harm normal cells, while causing minimal systemic side ef-
fects has become a major focus of today’s research.
Cardiac glycosides are a class of compounds used to treat
congestive heart failure and do so by increasing myocardial
contractile force [3]. Oleandrin is a cardiac glycoside derived
from Nerium oleander that has been used extensively over the
years in Russia and China for this purpose. In addition, over
the past century, oleander has been used in traditional reme-
dies and in commercial preparations in various parts of the
world for a multitude of ailments, including inflammation,
parasitic and bacterial infections, cardiac abnormalities, ring-
worm, skin diseases, swelling, vomiting, warts, and excessive
weight gain. Today, much of the focus on oleander research
has centered on anticancer and antiviral activities [4–8]. In
vitro, oleandrin has been shown to block ceramide-induced
NF-kappa B activation in a number of model biological sys-
tems including human epithelial and lymphoid cells, insect,
and murine macrophage cells [9]. Other studies have sug-
gested that oleandrin and PBI-05204 exhibit neuroprotective
effects against neural tissues damaged by oxygen and glucose
deprivation in ischemic stroke [10]. Cytotoxicity tests have
revealed a broad range of anti-proliferative efficacy against
various tumor cell lines including HeLa and A498 [11] as well
as inhibition of FGF-2 export in vitro from PC3 and DU145
prostate cancer cells in a concentration- and time-dependent
fashion which together contribute to the antitumor activity of
this novel treatment for cancer [12]. Preclinical and retrospec-
tive patient data suggest that cardiac glycosides (e.g. digoxin,
digitoxin, ouabain and oleandrin) affect the growth of various
cancers including breast, lung, prostate and leukemia [13]. For
example, oleandrin can inhibit the P-gp pump in HL60 and
K562 leukemia cell lines [14]. The relative sensitivity of
cancer cells to oleandrin treatment was shown to be species-
specific [15]; our laboratory has also shown that these com-
pounds induce selective cell death in certain human malignant
cells but not murine tumor cells or normal human cells, a
phenomenon likely mediated through both expression and
distribution of the α3 isoform of Na, K-ATPase the target to
which CGs bind [4, 16]. Although much has been published
on how oleandrin mediates its biological activity in vitro,
knowledge on how it inhibits tumor growth in the human
pancreatic cancer mouse orthotopic model remains limited.
In the present study, we evaluated the antitumor efficacy of
PBI-05204, a modified supercritical CO2 extract of Nerium
oleander, with or without gemcitabine, in a human pancreatic
cancer Panc-1 mouse orthotopic model in an attempt to un-
derstand its relative efficacy and underlying pharmacologic
mechanisms. The data obtained suggest that PBI-05204 exerts
potent antitumor efficacy, superior to that of gemcitabine
alone, a standard therapy for pancreatic cancer.
Materials and methods
Chemical, reagents and antibodies
Phospho-AKT, phospho-S6, and phospho-4EBP1were pur-
chased from Cell Signaling Technology (Beverly, MA). Ki-
67 was purchased from Thermoscientific (Waltham, MA) and
β-Actin was purchased from Sigma (St. Louis, MO). RNase
A and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) were also purchased from Sigma Chemical,
Co. PBI-05204, a supercritical CO2 extract, was prepared
from the leaves of organically grown Nerium oleander plants
by Flavex Naturextrakte (Rehlingen, Germany).
Cell lines and cell culture Human pancreatic cancer Panc-1
and Capan-II cells were obtained from the American Type
Culture Collection (Manassas, VA), maintained in a humidi-
fied atmosphere containing 5 % CO2 at 37 °C and were
routinely cultured in DMEM tissue culture medium
(Invitrogen Corp., Grand Island, NY) supplemented with
10 % heat inactivated fetal bovine serum ([FBS] Hyclone
Laboratories Inc., Logan, UT), 50 IU/ml penicillin and
50 μg/ml streptomycin, and 2 mM L-glutamine from
GIBCO (Invitrogen). All cell lines were authenticated via
microscopic morphology check and DNA characterization.
Animals and study design All animal study protocols were
approved by the Animal Care and Use Committee of the
University of Texas, M. D. Anderson Cancer Center. Female
balb/c nu/nu 6–8 weeks old mice were supplied by
Experimental Radiation Oncology, M. D. Anderson Cancer
Center, TX and were allowed to acclimatize for 3 days prior to
study initiation. Mice were fed AIN76 diet (Harlan,
Livermore, CA) and water ad libitum. For development of
the orthotopic model, mice were anesthetized with Ketamine:
Xylazine cocktail (150 mgkg: 7.5 mg/kg IP) followed with an
aseptic scrub process. The abdominal skin and muscle were
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incised just off the midline and directly above the pancreas to
allow visualization of the pancreatic lobes. The pancreas was
gently retracted and positioned to allow for direct injection of
a 50 μL bolus containing 1×106 Panc-1 cells/HBSS using a
1 cc syringe with a 30 gauge needle. The pancreas was placed
back within the abdominal cavity, and the muscle and skin
layers were closed with surgical sutures and staples. Analgesia
(Buprenorphine 0.05mg/kg SC) was given twice immediately
following surgery and 12 h later. Fourteen days after injection,
all animals that received orthotopic tumor cells inoculation
were imaged using an MR Scanner in the Small Animal
Imaging Facility (SAIF, MD Anderson Cancer Center, TX).
MR studies were performed on a 7Tscanner (Bruker Biospec,
Bruker Biospin, Billerica, MA) using a 60-mm gradient insert
and a volume resonator with a 35 mm inner diameter. Animals
were anesthetized and placed head first and prone on a posi-
tioning sled. Orthogonal 3-plane scout scans were initially
acquired for animal positioning. MR images were acquired
using a T2-weighted rapid acquisition with relaxation en-
hancement (RARE) pluse sequence repetition time (TR)
=2453.85 ms; echo time (TE) =38 ms; flip angle (FA)
=180°; field of view (FOV) =4×3×3 cm3; slice thickness
=0.75 mm, image matrix =256×192; number of signal aver-
ages =3). Only mice with positive tumor imaging were ran-
domized to seven different treatment groups including vehicle
control (25 %DMSO: 75% PEG400), PBI-05204 (10, 20 and
40 mg/kg), Gemcitabine (40 mg/kg) and PBI-05204/
Gemcitabine (10 and 20 mg/kg/40 mg/kg). PBI-05204 was
administered to mice via an oral gavage daily while
gemcitabine was given by i. p. injection three times per week
for 6 weeks. Animals were weighed weekly and observed
daily. MR Imaging was performed before treatment and
6 weeks after initial treatment with PBI-05024. At the end of
treatment, blood was collected by cardiac puncture and de-
tected pancreatic tumor was removed, weighed and measured.
Tumor tissues were either formalin fixed or flash frozen in
liquid nitrogen and then stored at −80 °C for future analysis.
Tumor burden was defined as total tumor volume multiplied
by the number of detectable tumors.
Histopathology and immunohistochemistry Tumor tissues,
pancreas and mesenterium were collected from PBI-05204
treated mice, fixed in neutral buffered formalin, and paraffin
processed for histopathological examination (H&E stained
sections) or biomarker identification by immunohistochemis-
try staining. For pancreas without macroscopically visible
tumors, the entire pancreas and mesenteric tissue were serially
sectioned and stained with H&E every 50 μm, and then were
examined microscopically. For IHC staining, 6 μm thick
sections were mounted on glass slides, and antigens were
unmasked using antigen retrieval. After washing in Tris buffer
solution, sections were incubated in a methanol peroxide
solution followed by blocking with normal goat serum and
BSA. Sections were incubated with monoclonal antibodies in
a humidified chamber overnight at 4 °C. After washing with
Tris buffer solution, an appropriate secondary antibody was
added and samples were incubated at room temperature for
45 min. For antibody visualization, sections were incubated
with ABC (Vector Laboratories, Burlingame, CA) followed
by DAB substrate and finally counterstained with Mayer’s
haematoxylin, dehydrated and mounted in Permount.
Immunostaining was assessed with an EVOS light micro-
scope (AMG, WA).
Determination of mouse plasma oleandrin content To prepare
samples for determination of oleandrin content, 0.2 mL of
plasma was diluted with 0.8 mL distilled water containing
100 ng/ml of cinobufatalin (internal standard) and then ap-
plied to a preconditioned Waters Oasis HLB solid phase
extraction cartridge (1 cc 30 mg, Waters Corp., Milford,
MA). The cartridge was then washed with 2 mL of water
and oleandrin was eluted with 1 mL of ethyl acetate followed
by 1 mL of methanol, after which the eluent was collected and
evaporated. The dried sample was then reconstituted in 200 μl
methanol: 0.2 % formic acid (1:1) prior to analysis by LC/MS/
MS.
Reverse-phase HPLC electrospray ionization MS was per-
formed using an Agilent 6460 triple quadruple tandem mass
spectrometer equipped with an Agilent 1200 HP binary pump
high-pressure LC inlet. Oleandrin was separated using a
Kinetex C18 2.6 μ (2×100 mm) LC column (Phenomenex,
Torrence, CA). The mobile phase consisted of 0.2 % formic
acid (aqueous), and methanol; the flow rate was 200 μl/min
and a column temperature was maintained at 35 °C. The
sample injection volume was 10 μl. The mass spectrometer
was operated in the electrospray positive ion mode with a
source temperature of 250°. The collision energy was 15 V for
oleandrin and 10 V for the internal standard. The multiple-
reaction monitoring (MRM) of the transition ions (M/Z)
577.3>373 for oleandrin and 459.2>363.1 for cinobufatalin
were used for identification and quantification of oleandrin.
Cytotoxicity determination Cells were grown at a density of
1×104 cells/well in their relevant media. After a 24 h incuba-
tion period, cells were treated with various concentrations of
PBI-05204 (0.2 to 100.0 μg/ml). After an additional 72 h,
inhibition of cellular proliferation was assessed byMTTassay
[17]. Absorbance was read at a wavelength of 570 nm and a
reference wavelength of 650 nm using a V-Max Micro-plate
Reader by Molecular Devices, Inc. (Sunnyvale, CA).
Cell cycle Cells were treated with PBI-05204 as previously
described. After 48 h treatment, cells were fixed with 70 %
ETOH for at least 24 h. They were then washed with PBS,
resuspended in PBS with PI (2 mg/ml) and RNase A solution
(10 mg/ml), and measured using a flow cytometer/cell sorter.
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Western blotting PANC-1 cells (1×106) were treated in serum-
free conditions with 0.125, 0.25, 0.5 and 1 ug/ml PBI-05204 for
24 h. Cells were washed with cold phosphate buffered saline
(PBS) and scraped with a lysis buffer (Invitrogen, Carlsbad,
CA) with protease inhibitor cocktail (Sigma, Inc., St. Louis,
MO) as an additive. Lysates were then sonicated on ice for
3 min., incubated for 10 min. and centrifuged at (14,000 g) for
10 min. at 4 °C. Protein levels were quantified via the BioRad
Dc protein assay (BioRad, Inc., Hercules, CA). Equal levels of
protein (50 μg) were fractionated on precast gels (BioRad) and
then transferred on polyvinylidene diflouride membranes ac-
cording to standard methods. Following a 1 h incubation in 5%
nonfat dry milk blocking buffer prepared in tris-buffered saline
with 0.1 % tween 20 (TBS-T), membranes were probed with
primary antibodies diluted 1:1000 in blocking buffer. Protein
bands were visualized via chemiluminesence using the ECL +
detection kit and hyper-film (Amersham Biosciences,
Piscataway, NJ). Equal loading of samples was assessed by
Western blotting for relative β-Actin content.
Statistical analysis Student’s t-test or Mann-Whitney U test
was used to determine the statistical differences between
various experimental groups; a value of P≤0.05 was consid-
ered to be significant.
Results
PBI-05204 substantially inhibited the proliferation of Panc-1
mouse orthotopic tumors
To investigate the efficacy of PBI-05204 alone or in combina-
tion with a standard of care therapeutic agent for treatment of
pancreatic cancer orthotopic tumors, mice bearing human pan-
creatic cancer Panc-1 cells were treated with PBI-05204 or
gemcitabine individually or with a combination of both agents.
PBI-05204 markedly and dose dependently inhibited the
growth of Panc-1 tumor as evidenced both by a reduction of
tumor weight (Fig. 1a) and tumor burden (Fig. 1b) while
gemcitabine alone did not show any significant antitumor
effect. The measurable tumor incidence was dose dependently
reduced in PBI-05204 treated mice compared to vehicle treated
group. The average tumor weight (222.9±116.9 mg) in mice
treated with PBI-05204 (20 mg/kg) was significantly reduced
from that in controls (920.0±430.0 mg) (p<0.05) (Fig. 1a).
This represented an average 75.8 % decline in tumor weight.
The reduction of tumor growth by PBI-05204 (40 mg/kg) was
remarkable and significant; all control mice exhibited
dissectible tumors by the end of the treatment period while
only 2 out of 8 mice (25%) treated for 6 weeks with PBI-05204
(40 mg/kg) showed measureable pancreatic disease (p<0.009,
n=8). The tumor sizes in both control and PBI-05204
(40 mg/kg) groups were similar before treatment (Fig. 2a, d
and g).While the tumor sizes grew substantially in control mice
(Fig. 2b), the majority of PBI-05204 (40 mg/kg) treated mice
showed either no visible tumors or reduced tumor size after
6 weeks of treatment (Fig. 2e or h). These findings were further
supported by the necropsy of normal appearing pancreas in
PBI-05204 treated Panc-1 bearing mice (Fig. 2f) compared to
that of control mice (Fig. 2c). In contrast, gemcitabine
(40 mg/kg) reduced neither tumor incidence nor growth of this
particular tumor (Fig. 1). Mice treated with 125 mg/kg of
gemcitabine also failed to show any significant antitumor effi-
cacy (data not shown). When mice were treated with PBI-
05204 (20mg/kg) and gemcitabine together, both tumor weight
and tumor burden were significantly reduced compared to that
of control group and gemcitabine alone group (P=0.038, n=8
and P=0.013, n=8, respectively) (Fig. 1).
Anatomical and histological examination
of PBI-05205-treated pancreatic tumors
To further confirm the presence of orthotopic pancreatic tu-
mors, the pancreas with tumor tissue were processed histolog-
ically in H&E stained sections that were examined microscop-
ically by a certified pathologist. Pancreases without grossly
detectable tumor were serially sectioned along with the
mesenterium at 50 μm intervals and stained with H&E for
histological examination. Detected pancreatic tumors were
analyzed morphometrically. Histological examination of
H&E stained tissue sections from PBI-05204 treated (0, 10,
20, 40 mg/kg) mice revealed a dose dependent decrease in
tumor size (Fig. 3b–d) compared to that of vehicle control
group (Fig. 3a). Intriguingly, histological examination of
H&E stained tissue of the serially sectioned pancreas from
PBI-05204 (40 mg/kg) treated mice presented with either no
detectable tumor cells (5/6) or significantly smaller tumor
sizes with diameters less than 2.3 mm (1/6). Given that
oleandrin, a major component of PBI-05204, is known to
inhibit the proliferation of Panc-1 cells [4], the plasma con-
centration of oleandrin was analyzed inmice treated with PBI-
05204. Figure 3e showed that plasma oleandrin in PBI treated
mice increased from an undetectable level (vehicle control) to
2.298±0.945 ng/ml in PBI-05204 (40 mg/kg) treated group
collected 4 h after the last dose of PBI-05204.
PBI-05204 inhibited proliferation of Panc-1 orthotopic tumors
and in vitro in the Panc-1 cells
To further evaluate the impact of PBI-05205 on cell prolifer-
ation of Panc-1 tumors, the relative anti-proliferative capacity
in control and PBI-treated mice were examined by Ki-67
staining. As shown in Fig. 4A, Ki-67 staining was markedly
reduced by PBI-05204 compared to that in tissues from vehi-
cle treated mice. Similarly, PBI-05204 inhibited the prolifera-
tion of Panc-1 and CaPanII human pancreatic cancer cell lines
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with an IC50 of about 10 μg/ml (Fig. 4B). At a 1 μg/ml
concentration, PBI-05204 showed about a 5-fold increase in
cells at the subG1 phase of the cell cycle, indicative of apo-
ptosis. PBI-05204 treatment led to a concentration dependent
reduction of proliferation in Panc-1 cells (Fig. 4C).
PBI-05204 inhibited PI3kinase/mTOR pathway
To understand the molecular mechanisms that are associated
with PBI-05204 induced tumor suppressive effects, tumor
tissues were subjected to an examination of PI3kinase/
mTOR pathways that had previously been reported by us as
being involved in the antitumor effect of oleandrin [4]. As
shown in Fig. 5, the immunohistochemical staining of
phosphorylated Akt, S6 and 4EBP1 in PBI-05204 (10 and
20 mg/kg) treated tumor tissue were all notably reduced
compared to that of the control vehicle treated group. When
Panc-1 cells were treated with PBI-05204 (0.125 to 1 μg/ml)
for 24 h, the expression of these three cell signaling proteins
were also down regulated in a concentration dependent man-
ner, suggesting involvement of the PI3K/Akt/mTOR path-
ways in PBI-05204 elicited antitumor activity (Fig. 6).
Discussion
In the present study, we investigated the role of a natural
product containing oleandrin, a supercritical CO2 extract of
P = 0.009
P = 0.054
PBI (mg/kg)        - 10      20      40       - 10      20
Gemz (mg/kg)    - - - - 40     40      40 
P = 0.009
P = 0.038a b 
Fig. 1 Tumor weight (a) and tumor burden (b) of human
pancreatic cancer Panc-1 mouse orthotopic model treated with
PBI-05204, gemcitabine (Gemz) or a combination of PBI-05204
and gemcitabine for 6 weeks. PBI-05204 but not gemcitabine
significantly inhibited the growth of Panc-1 tumors. Data are
presented as Mean±SD (n=7 for the control and 8 for each treatment











































Fig. 2 In vivo MR imaging
shows that PBI-05204 reduces the
growth of established Panc-1
tumors. Representative, axial MR
(a, b, d, e, g and h) and coronal
necropsy (c and f) images of nude
mice (representative control and
treatment group mice are shown).
Treatment with PBI-05204 at a
dose of 40 mg/kg daily via an oral
gavage or vehicle was begun on
day 14. MR imaging using a
T2-weighted rapid acquisition
with relaxation enhancement
(RARE) pulse sequence was done
2 and 8 weeks after Panc-1
inoculation. T, pancreatic tumor.
K, kidney. Sp, spleen. Yellow
arrows indicate pancreatic tumor
tissue in vehicle treated Panc-1
tumor bearing mice (c) whereas
an example
PBI-05204 (40 mg/kg) treated
mouse showed normal looking
pancreas (f)
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Nerium oleander (PBI-05204), on pancreatic tumor growth
in vivo and in vitro. Our results show that PBI-05204 signif-
icantly inhibited the peritoneal dissemination of orthotopically
implanted Panc-1 cells in nude mice along with inhibition of
proliferation and induction of apoptosis. Furthermore, PBI-
05204 significantly down-regulated the expression of
biomarkers relevant to PI3k/Akt and mTOR pathways
in vivo and in vitro, indicating that PBI-05204 targets com-
ponents of the PI3k/Akt/mTOR pathway to inhibit the growth
of primary tumors. Given that a recent study using patient
derived human pancreatic cancer xenograft models and their
primary tumor suggests that cardiac glycosides, including





Fig. 3 Mouse pancreas bearing orthotopic Panc-1 human tumor, H&E
stained sections. a. vehicle control; b. PBI-05204 (10 mg/kg); c. PBI-
05204 (20 mg/kg); d. PBI-05204 (40 mg/kg). Histological examination
of tissue sections showed that PBI-05204 inhibited Panc-1 tumor
development in a concentration dependent manner. Pancreatic tumor is
significantly smaller in 40 mg/Kg PBI-05204 treated mice (black arrow
indicating a tumor of less than 100 μm diameter) in comparison with
1.039 mm diameter tumor (green arrow) in 20 mg/Kg PBI-05204 treated
mice, 2.659 mm diameter tumor (green arrow) in 10 mg/Kg PBI-05204
treated mice, and 4.678 mm diameter tumor in control mice. E. Plasma
concentration of oleandrin in mice treated with vehicle control or PBI-
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a 100 M b 100 M c 100 M
Fig. 4 PBI-05204 markedly inhibited tumor proliferation in the Panc-1
orthotopic model as evidenced by a reduction of Ki-67 staining (A) and in
human pancreatic cancer cells (B) by induction of apoptosis (C). A, a).
Vehicle control; b) PBI-05204 (10 mg/kg); c) PBI-05204 (20 mg/kg). B.
Proliferation of Panc-1 and CaPan-II cells treated with PBI-05204 for
72 h measured by MTT assay. C. PI staining of Panc-1 cells treated with
PBI-05204 for 48 h. * P<0.05 PBI-05204 treated versus vehicle treated
group
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digoxin, digitoxin and ouabain, inhibit the proliferation of
both primary cancer cells and their xenograft tissues [18],
our study for the first time demonstrates a natural prod-
uct containing oleandrin that has already completed a
successful clinical Phase I safety trial has the ability to
strongly inhibit the growth of human pancreatic cancer in an
orthotopic model.
Cardiac glycosides, such as digoxin or digitoxin, are main-
ly used for the treatment of congestive heart failure. The initial
observation of the potential impact of cardiac glycosides on
cancer development occurred in 1979, when Dr. Stenkvist’s
studies suggested that breast cancer patients who were on
digoxin for treatment of congestive heart failure showed a
more benign phenotype of their malignant disease than those
patients not receiving cardiac glycoside therapy [19, 20].
Since this initial clinical observation, there has been an in-
creased interest in the effect of cardiac glycosides on cancer
growth. A large body of literature now indicates that various
cardiac glycosides, including both cardienolides (digoxin,
digitoxin, oleandrin) and bufadienolides (bufalin, cinobufagin
and cinobufotalin), exert important anticancer activity in
various human tumor cell and xenograft models [21–26].
Most recently, a study further supports cardiac glycoside
mediated anticancer activity in human pancreatic cancer.
Authors showed that among over 2000 compounds that had
been screened, three cardiac glycosides, digoxin, digitoxin
and ouabain, had strong anticancer activity against both pri-
mary human pancreatic cancers and their xenograft models
[18]. Additionally, studies have also documented that bufalin
inhibits human tumor mouse orthotopic models of human
hepatocellular carcinoma while UNBS1450 inhibited the
growth of glioblastoma [27, 28]. We and others have previ-
ously demonstrated that oleandrin inhibits the proliferation of
human pancreatic cancer cells, Panc-1 and MiaPaca, human
colon cancer cells, melanoma and non-small cell lung cancer
cells by either induction of apoptosis or autophagic cell death
[4, 7, 16]. In light of the anti-proliferative activity of oleandrin
and the supercritical CO2 extract of Nerium oleander in hu-
man pancreatic cancer Panc-1 cells being very similar when
they are normalized to relative oleandrin concentrations (data
not shown), we examined the antitumor efficacy of PBI-
05204, a supercritical CO2 extract of Nerium oleander, in
human pancreatic cancer Panc-1 orthotopic models and have
shown that PBI-05204 not only dose dependently slows the
growth of this particular tumor, it almost totally eradicates
tumor growth at the highest dose (40 mg/kg) after 6 weeks of
treatment. In comparison, the standard therapeutic agent
gemcitabine (at either 40 or 125 mg/kg) failed to suppress
the proliferation of this particular orthotopic tumor model.
Intriguingly, the plasma oleandrin levels in PBI-05204
(40 mg/kg) treated mice were previously found to be achiev-
able in humans without any cardiac toxicity based on the
result of a phase I trial of PBI-05204 [29].
Pancreatic ductal adenocarcinoma (PDA) remains one of
the most aggressive tumors in humans with a 5-year survival
rate of less than 5 %[30]. The standard systemic chemother-
apy for PDA is gemcitabine following its approval for this
disease in 1997. However, treatment with gemcitabine results
in only a marginal increase in pancreatic cancer patient sur-
vival. Because of this poor response, many efforts have been
focused on improving the therapeutic potential of gemcitabine
in PDA through a combination of radiation, chemotherapy as
well as targeted therapeutic agents [31–34]. Among more than
a dozen combination therapy trials, only a few, such as
gemcitabine and Abraxane, have shown any improved sur-
vival benefit compared to gemcitabine alone. Clearly, new
targets or therapeutic approaches are needed for this disease.
In our model, gemcitabine alone failed to demonstrate any
tumor suppressive effect, which was consistent with results of
previous studies [35]. When mice with Panc-1 orthotopic
tumors were treated with a combination of PBI-05204
(20 mg/kg) with gemcitabine (40 mg/kg), tumor growth was
significantly and substantially slower compared to mice treat-




0                               10                             20                        PBI-05204 (mg/kg)
Fig. 5 Oral administration of PBI-05204 down regulated the PI3kinase/
mTOR pathway proteins in human Panc-1 orthotopic tumors. Tumor
sections were obtained by the end of 6 weeks treatment and stained
with antibodies raised against pAkt (Ser473), pS6 (Ser 235/236) and
p4EBP1 (Thr37/46) proteins and counter stained with hematoxylin
Fig. 6 PBI-05204 inhibited the expression of signaling proteins
associated with PI3kinase/mTOR pathways in Panc-1 cells. Panc-1 cells
were treated with DMSO or PBI-05204 (0.25 to 1 μg/ml) for 24 h. The
proteins of interest were measured by western blotting. P. Parental Panc-1
cells without treatment
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tumor growth in gemcitabine and PBI-05204 treated mice was
also stronger than that of PBI-05204 (20 mg/kg) treated mice.
One of the limitations of this study is that the Panc-1
xenograft model responded poorly to gemcitabine treatment
alone which may have been due to the lack of expression of
S100P protein [35]. To be useful clinically, further studies will
be needed to determine whether PBI-05204 can potentiate the
therapeutic effect of gemcitabine as well as other approved
chemotherapeutic agents in human pancreatic cancer
orthotopic models that are relatively responsive to treatment
of gemcitabine, such as MiaPaca and AsPC-1 cells. Such
studies are currently underway.
While a large body of evidence suggests that cardiac gly-
cosides exert anticancer activity against various cancers in-
cluding both solid and non-solid malignant diseases, numer-
ous molecular mechanisms responsible for the antitumoral
effect of CGs have been proposed [24]. Suggested targets
include NF-kB, ERK and PI3kinase pathways. We have pre-
viously reported that oleandrin down regulates phosphoryla-
tion of Akt in Panc-1 cells, and that addition of activated Akt
abrogates the oleandrin elicited anticancer activity in these
particular cells [7]. Similarly, dephosphorylation of Akt or
inhibition of Akt phosphorylation was observed in U937 cells
or TPA-induced activation of PI3kinase/Akt in mouse skin
treated with oleandrin, respectively [36, 37]. Additionally,
Zhang D. et al. demonstrated that aerobufalin, a bioactive
component of bufo toad, induces apoptosis by inhibiting both
PI3kinase/mTOR pathways in human hepatocellular carcino-
ma HepG2 cells [38]. Notably, in this current study, PBI-
05204 treatment led to down-regulation of both PI3kinase/
mTOR pathways as evidenced by reduced expression of
pAKT, pS6 and p4EBP1 in both Panc-1 cells and its relevant
orthotropic model. This provides scientific support to the
results of the phase I trial of PBI-05204 which also showed
that both PI3kinase/mTOR signaling pathways were down
regulated in PBMCs of some patients enrolled in the study
[26]. In fact, the down regulation of pS6 appeared to be more
pronounced than that of the reduction of pAkt in both the
Panc-1 orthotopic model and PBMCs of phase I patient sam-
ples [29], which suggests that the down regulation of the
mTOR pathway is important in PBI-05204 elicited antitumor
activities. In addition to PDA, emerging evidence supports
that PI3kinase/mTOR pathways are critical in pancreatic neu-
roendocrine tumors (PanNETs) due to PTEN deletion, tuber-
ous sclerosis complex mutation and activation of Akt and
mTOR [39]. Studies of the impact of PBI-05204 in human
PanNETs may be interesting and informative.
In conclusion, we have used an orthotopic model of human
pancreatic Panc-1 cancer to identify the antitumor efficacy of
PBI-05024 and its relevant molecular mechanisms. Compared
to gemcitabine, the commonly used chemotherapeutic agent
for PDA, PBI-05204 exhibited strong monotherapeutic anti-
neoplastic effects through down regulation of PI3k/mTOR
pathways and augmentation of the antitumor efficacy of
gemcitabine. Given that the phase I clinical trial of PBI-
05204 showed very limited cardiac toxicity, these data provide
further support for PBI-05204 as a potential anticancer thera-
peutic agent for pancreatic cancer that warrants further clinical
investigation.
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